UncleBilly, yes profit potential is HUGE! This from Bioclonetics own site:
Technology Potential
Projected Earnings from the BioClonetics’ passive immunotherapy have been calculated by an independent national consulting firm. This analysis examines the expected potential profits from 2 perspectives: (1) considering sales only to North America and Western Europe and (2) considering sales to the major Markets including North America, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America. The potential earnings and underlying assumptions for application of our passive immunotherapy to major Markets are set forth here:
Potential Profit from Technology
A most appropriate market for the Company’s therapy includes the regions referred to as the “Major Markets”, including North American, Western and Central Europe, Eastern Europe and Central Asia, South and Southeast Asia and Latin America wherein there are 10.6 million HIV positive individuals. Assuming a penetration rate of 1% rising to a maximum 15% over a five-year period, profit from making treatment available to these 10.6 million HIV positive individuals in the 7 major world markets would be $105 billion in the first 11 years.
THINK ABOUT THAT! Even with limited penetration into the HIV Market is worth $30+/share... What if we get 50%? 90%? If Clone3 really CURES the disease and a person will not have regime Meds for life, Would anyone go to another drug?
This $ Figure is ONLY HIV CONSIDERED.....If any or All of the others pan out, ¡CHIHUAHUA!
News 
Market Data 
Discover 
